PDF-HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include a

Dermatologic ToxicityTemporarily interruptPOTELIGEO for moderate or severe skin rashes Permanently discontinue POTELIGEO for lifethreatening rash 51InfusionReactionsTemporarily interruptfor any infusi. --------------------------RECENT MAJOR CHANGES---------------------------- Boxed Warning 04/15 Indications and Usage (1.1) 04/15 Dosage and Administration (2.1, 2.2) 04/15 Warnings a NDA 22-288/S-003 Reference ID: 3151309 NDA 22-288/S-003 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a histamine H receptor antagoni What’s different about paediatric prescribing. Children are just . small adults. NOT!. Vary in their developmental stages. Pre-term, neonates, infants, children, adolescents. Dynamic anatomy and physiology. Marie Bradley*, . Tom Fahey**, . Caitriona. . Cahir. **, Kathleen Bennett***, Dermot O’Reilly****, . Carmel M. Hughes*. IN INPATIENT EATING DISORDER MANAGEMENT. Steven Voy (. S.J.Voy@sms.ed.ac.uk. ). Supervisor: Dr Jane Morris. Majority. should be managed on an outpatient basis. Should consist of:. Psychological therapies. Peter Pratt. Chief Pharmacist. Sheffield health & social care NHS FT Trust. Peter.pratt@shsc.nhs.uk. Disclosure statement. NHS only source of income. No interest or relationships with any companies of agents associated with . Anthony Oxley – Head of Pharmacy. The Driver for Implementing EPMA?. Mental Health, Learning Disability and Community Health Services.. Prince2 Project . JAC User. Leicestershire Partnership NHS Trust. Outline. Antibiotic prescribing across the U.S.. What is known about antibiotic prescribing in New York State. CDC’s Get Smart program. Our antibiotic prescribing project. Resources. Slide from CDC Get Smart Program. Andrew Oates. Lower Limb Specialist Physiotherapist. CDDFT. Aims. Introduce the University course structure including assessment criteria.. Review the expectations within practice.. Briefly review the ‘storey so far’ of non-medical prescribing.. __________________________________________________________________ FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Jakafi is indicated for treatment of patients with intermediate or high-risk Limitation of Use Should only be used for acute treatment periods up to two or three weeks (1)------------------------DOSAGE AND ADMINISTRATION------------------- DESCRIPTIONCLINCIAL PHARMACOLOGY12.1 Reference ID 4330857FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudom treatment and adjust dosing as needed 22 51 constipation nausea and vomiting as needed 22 52 Peripheral Neuropathy Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed 2 WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of BOTOXand all botulinum toxin products may spread from the area of injection to produ